BriaCell Therapeutics Corp.
BCTX
$10.41
$0.333.27%
NASDAQ
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -566.40% | -457.09% | 44.30% | -196.68% | 49.80% |
| Total Depreciation and Amortization | -63.12% | 602.63% | 602.63% | 602.63% | 1,805.26% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 88.68% | 100.13% | -125.68% | 106.73% | 8.12% |
| Change in Net Operating Assets | -68.59% | -128.80% | -52.78% | -1,268.94% | 132.79% |
| Cash from Operations | -101.51% | -40.89% | 20.01% | 8.55% | 63.04% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 53.33% | -- | -- | -- |
| Cash from Investing | -1,517.99% | 53.33% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 206.80% | -- | -- | -- | 10.47% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 206.80% | -- | -- | -- | 10.47% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2,571.74% | 240.27% | 89.48% | 164.83% | 98.94% |